Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
D015703:Antigens, CD; D018941:Antigens, CD19 / Q000276:immunology; D002051:Burkitt Lymphoma / Q000473:pathology / Q000628:therapy*; D017252:CD3 Complex / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D016827:CD8 Antigens / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D018796:Immunoconjugates / Q000235:genetics / Q000494:pharmacology; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000494:pharmacology; D007167:Immunotherapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy*; D017434:Protein Structure, Tertiary; D017475:Receptors, Nerve Growth Factor / Q000235:genetics / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014161:Transduction, Genetic; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9
D015703:Antigens, CD; D018941:Antigens, CD19; D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D016827:CD8 Antigens; D018796:Immunoconjugates; D007135:Immunoglobulin Variable Region; D017475:Receptors, Nerve Growth Factor; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; C505714:TNFRSF9 protein, human; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9